Novartis’s Alcon cares project 100 commits to reducing cataract blindness globally
Alcon, a division of Novartis, will give 100 reprocessed Infiniti units to eligible clinics in Asia, Central and South America,…
Pharmaceuticals, Biotechnology and Life Sciences
Alcon, a division of Novartis, will give 100 reprocessed Infiniti units to eligible clinics in Asia, Central and South America,…
Novartis announced the launch of its FocalView app, an ophthalmic digital research platform created with ResearchKit. FocalView aims to allow…
Novartis has announced a new post hoc analysis of the pivotal Phase III heart failure study, PARADIGM-HF, which showed that…
Novartis’s acquisition of the US-based Nasdaq-listed clinical stage gene therapy company AveXis for $218 per share, for total of 8.7…
Novartis will sell its 36.5 percent stake in its consumer healthcare joint venture (JV) to GSK for $13.0 billion, it…
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion…
Novartis could have the first therapy which could delay disability progression secondary progressive multiple sclerosis (SPMS) if it gets the…
Novartis has teamed up with scientists from the Wyss Institute for Biologically Inspired Engineering at Harvard University and the Dana-Farber…
Novartis has made several changes as it added several figures in the team starting April, while its Operations president, André…
Novartis aims to initiate up to 10 new clinical trials over the next three year with a leader in decentralized clinical trial…